Generation of Anti-Idiotype scFv for Pharmacokinetic Measurement in Lymphoma Patients Treated with Chimera Anti-CD22 Antibody SM03
Publication in refereed journal


Times Cited
Web of Science1WOS source URL (as at 26/09/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractPre-clinical and clinical studies of therapeutic antibodies require highly specific reagents to examine their immune responses, bio-distributions, immunogenicity, and pharmacodynamics in patients. Selective antigen-mimicking anti-idiotype antibody facilitates the assessment of therapeutic antibody in the detection, quantitation and characterization of antibody immune responses. Using mouse specific degenerate primer pairs and splenocytic RNA, we generated an idiotype antibody-immunized phage-displayed scFv library in which an anti-idiotype antibody against the therapeutic chimera anti-CD22 antibody SM03 was isolated. The anti-idiotype scFv recognized the idiotype of anti-CD22 antibody and inhibited binding of SM03 to CD22 on Raji cell surface. The anti-idiotype scFv was subsequently classified as Ab2 gamma type. Moreover, our results also demonstrated firstly that the anti-idiotype scFv could be used for pharmacokinetic measurement of circulating residual antibody in lymphoma patients treated with chimera anti-CD22 monoclonal antibody SM03. Of important, the present approach could be easily adopted to generate anti-idiotype antibodies for therapeutic antibodies targeting membrane proteins, saving the cost and time for producing a soluble antigen.
All Author(s) ListZhao Q, Wong PF, Lee SST, Leung SO, Cheung WT, Wang JZ
Journal namePLoS ONE
Detailed descriptionTo ORKTS: Wing Tai Cheung and Jun-zhi Wang are the co-corresponding authors.
Year2014
Month5
Day9
Volume Number9
Issue Number5
PublisherPUBLIC LIBRARY SCIENCE
ISSN1932-6203
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesMultidisciplinary Sciences; MULTIDISCIPLINARY SCIENCES; Science & Technology - Other Topics

Last updated on 2020-27-09 at 01:41